These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31070862)

  • 1. Nummular dermatitis on guselkumab for palmoplantar psoriasis.
    Truong A; Le S; Kiuru M; Maverakis E
    Dermatol Ther; 2019 Jul; 32(4):e12954. PubMed ID: 31070862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.
    Napolitano M; Scalvenzi M; Fabbrocini G; Cinelli E; Patruno C
    Dermatol Ther; 2019 Nov; 32(6):e13142. PubMed ID: 31664761
    [No Abstract]   [Full Text] [Related]  

  • 3. Local injection of micro-dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment.
    Zhou C; Chen D; Diao Z; Wang Y; Hou Y; Yin Z
    Australas J Dermatol; 2024 May; 65(3):e75-e76. PubMed ID: 38439213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 5. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 6. A Case of Ixekizumab-induced Psoriasiform Eruption.
    Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T
    Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-Interleukin 23-Based Therapies May Shift Cutaneous Immune Responses: A Case of New-Onset Contact Dermatitis to Carbamates After Guselkumab for Psoriasis.
    Liakos W; Toussi A; Le ST; Ma C; Merleev A; Marusina AI; Luxardi G; Konia TH; Sood A; Wu PA; Maverakis E
    Dermatitis; 2021 Nov-Dec 01; 32(6):e113-e115. PubMed ID: 34138776
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 9. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 10. Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction.
    Hosokawa Y; Hamada T; Ashida H; Ikeda M
    J Dermatol; 2019 Aug; 46(8):e302-e303. PubMed ID: 30861165
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 12. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 13. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
    de Groot M; de Rie MA; Bos JD
    Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
    [No Abstract]   [Full Text] [Related]  

  • 14. Debut Of Inflammatory Bowel Disease Associated To Ixekizumab In Patient With Moderate, Difficult -To-Manage Psoriasis.
    Merino Gallego E; Gómez Torres K; Martínez Amate E
    Gastroenterol Hepatol; 2020 Dec; 43(10):622-623. PubMed ID: 32674878
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple paradoxical reactions during ixekizumab therapy.
    Pirro F; Caldarola G; De Simone C; Moretta G; Giovanardi G; Peris K
    Dermatol Ther; 2019 May; 32(3):e12852. PubMed ID: 30747476
    [No Abstract]   [Full Text] [Related]  

  • 16. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
    JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.
    Xiao Y; Peng S; Li X; Mao T; Fang M; Hu Y; Ye W
    Medicine (Baltimore); 2023 Feb; 102(6):e32844. PubMed ID: 36820537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
    Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.